title: Efficacy of carboplatin and paclitaxel with bevacizumab as salvage chemotherapy for non-small cell lung cancer after failure of platinum-doublet chemotherapy.
abstract: BACKGROUND
  Salvage chemotherapy using carboplatin (C), paclitaxel (P), and bevacizumab (BEV) for patients with pre-treated, advanced non-squamous non-small cell lung cancer (NSCLC) has not yet been reported.
  
  
  METHODS
  Medical records of patients with non-squamous NSCLC who received CP plus BEV between November 2009 and September 2011 and experienced progression after at least one platinum-based-chemotherapy regimen, were examined in this retrospective study.
  
  
  RESULTS
  Twenty-one patients were eligible for this study. The median number of prior chemotherapy regimens was 3 (range, 2 to 9). The median number of cycles of CP with BEV was 4 (range, 1 to 6). Seven patients underwent BEV maintenance therapy, and the median number of cycles of BEV maintenance was 8 (range, 2 to 13). Toxicity levels were acceptable. The overall median survival time was not reached and one-year survival rate was 54.95%. The overall progression-free survival was 6.1 months (95% confidence interval, 4.4-9.3 months).
  
  
  CONCLUSIONS
  CP with BEV was effective and feasible as a salvage chemotherapy after failure of platinum-based chemotherapy for patients with non-squamous NSCLC.
authors: Department of Thoracic Oncology, Kinki-Chuo Chest Medical Center, 591-8555, 1180 Nagasonecho, Sakai-City, Osaka, Japan.
authors: Motohiro
authors: M
authors: Tamiya
authors: Akihiro
authors: A
authors: Tamiya
authors: Keiko
authors: K
authors: Nakao
authors: Kazuhiro
authors: K
authors: Asami
authors: Kyoichi
authors: K
authors: Okishio
authors: Morita
authors: M
authors: Satomu
authors: Takayuki
authors: T
authors: Shiroyama
authors: Naoko
authors: N
authors: Morishita
authors: Hidekazu
authors: H
authors: Suzuki
authors: Shinji
authors: S
authors: Sasada
authors: Norio
authors: N
authors: Okamoto
authors: Kyoichi
authors: K
authors: Okishio
authors: Tomoya
authors: T
authors: Kawaguchi
authors: Masashi
authors: M
authors: Kobayashi
authors: Shinji
authors: S
authors: Atagi
authors: Tomonori
authors: T
authors: Hirashima
authors: Ichiro
authors: I
authors: Kawase
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D016190:Carboplatin / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage; D012189:Retrospective Studies; D016879:Salvage Therapy
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D016190:Carboplatin; D017239:Paclitaxel